AR031682A1 - Composiciones farmaceuticas - Google Patents
Composiciones farmaceuticasInfo
- Publication number
- AR031682A1 AR031682A1 ARP000106062A ARP000106062A AR031682A1 AR 031682 A1 AR031682 A1 AR 031682A1 AR P000106062 A ARP000106062 A AR P000106062A AR P000106062 A ARP000106062 A AR P000106062A AR 031682 A1 AR031682 A1 AR 031682A1
- Authority
- AR
- Argentina
- Prior art keywords
- buprenorphine
- naltrexone
- naloxone
- amount
- nalmefen
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 abstract 3
- 229960001736 buprenorphine Drugs 0.000 abstract 3
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 abstract 3
- 229960003086 naltrexone Drugs 0.000 abstract 3
- 230000000202 analgesic effect Effects 0.000 abstract 2
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 abstract 2
- 229960004127 naloxone Drugs 0.000 abstract 2
- SFNLWIKOKQVFPB-KZCPYJDTSA-N bunavail Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C.C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 SFNLWIKOKQVFPB-KZCPYJDTSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composicion analgésica bajo la forma de una unidad de dosificacion parenteral o bajo la forma de una unidad de dosificacion adecuada para una administracion vía mucosa que comprende una cantidad de buprenorfina que es menor a la dosis clínica requerida para lograr el alivio del dolor y una cantidad de naloxona tal que la relacion de peso entre buprenorfina y naloxona está en el rango de entre 2,5 a 1 y 27,5 a 1 o una cantidad de naltrexona o de nalmefen tal que la relacion de peso entre la buprenorfina y la naltrexona o el almefen está en el rango de entre 12, 5 a 1 y 22, 5 a 1, donde la accion analgésica de la buprenorfina se ve potenciada por la baja dosis de naloxona de naltrexona y de nalmefen.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9927359.1A GB9927359D0 (en) | 1999-11-19 | 1999-11-19 | Improvements in or relating to organic compositions |
| US17620800P | 2000-01-14 | 2000-01-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031682A1 true AR031682A1 (es) | 2003-10-01 |
Family
ID=26316086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000106062A AR031682A1 (es) | 1999-11-19 | 2000-11-16 | Composiciones farmaceuticas |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US6995169B2 (es) |
| EP (1) | EP1242087B1 (es) |
| JP (1) | JP4745576B2 (es) |
| KR (1) | KR100726699B1 (es) |
| CN (1) | CN100431543C (es) |
| AR (1) | AR031682A1 (es) |
| AT (1) | ATE262335T1 (es) |
| AU (1) | AU777259B2 (es) |
| BR (1) | BR0015580A (es) |
| CA (1) | CA2392013C (es) |
| CO (1) | CO5261517A1 (es) |
| CZ (1) | CZ303160B6 (es) |
| DE (1) | DE60009346T2 (es) |
| DK (1) | DK1242087T3 (es) |
| ES (1) | ES2214334T3 (es) |
| GB (1) | GB2356348B (es) |
| HU (1) | HU229565B1 (es) |
| IL (2) | IL149580A0 (es) |
| MX (1) | MXPA02004978A (es) |
| NO (1) | NO321965B1 (es) |
| NZ (1) | NZ519023A (es) |
| PL (1) | PL199727B1 (es) |
| PT (1) | PT1242087E (es) |
| RO (1) | RO121174B1 (es) |
| RU (1) | RU2255737C2 (es) |
| SI (1) | SI21025B (es) |
| SK (1) | SK286888B6 (es) |
| TR (1) | TR200400653T4 (es) |
| TW (1) | TW550070B (es) |
| WO (1) | WO2001035942A2 (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
| US20150031718A1 (en) * | 2001-08-06 | 2015-01-29 | Purdue Pharma L.P. | Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent |
| US20030068375A1 (en) | 2001-08-06 | 2003-04-10 | Curtis Wright | Pharmaceutical formulation containing gelling agent |
| US7666876B2 (en) * | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
| GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| KR101167579B1 (ko) | 2003-04-29 | 2012-07-27 | 오렉시젠 세러퓨틱스 인크. | 체중감량용 조성물 |
| ES2653568T3 (es) | 2004-06-12 | 2018-02-07 | Collegium Pharmaceutical, Inc. | Formulaciones de fármacos para la prevención del abuso |
| PT2135603E (pt) * | 2005-11-22 | 2013-04-03 | Orexigen Therapeutics Inc | Composições e métodos para aumentar a sensibilidade à insulina |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| US8916195B2 (en) * | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| EP1897543A1 (en) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine- wafer for drug substitution therapy |
| US20080125592A1 (en) * | 2006-10-17 | 2008-05-29 | Penick Corporation | Process for preparing oxymorphone, naltrexone, and buprenorphine |
| CA2674915C (en) * | 2006-10-17 | 2015-06-30 | Penick Corporation | Process for preparing oxymorphone |
| EP2089010A1 (en) | 2006-10-24 | 2009-08-19 | The John Hopkins University | Rapid release mini-tablets provide analgesia in laboratory animals |
| WO2008060964A2 (en) | 2006-11-09 | 2008-05-22 | Orexigen Therapeutics, Inc. | Unit dosage package and methods for administering weight loss medications |
| US20080199407A1 (en) | 2007-02-15 | 2008-08-21 | Slater Kenneth C | Drug Detoxification Protocol Using Microdosing |
| GB2447013A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition containing buprenorphone and nalmefene |
| GB2447014A (en) | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
| GB2447015A (en) | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Analgesic composition comprising a specific ratio of buprenorphine and naltrexone |
| GB2447016A (en) * | 2007-03-01 | 2008-09-03 | Reckitt Benckiser Healthcare | Buprenorphine/naloxone compositions |
| HUE027537T2 (en) * | 2007-09-03 | 2016-10-28 | Nanotherapeutics Inc | Granular preparations for the administration of poorly soluble drugs |
| US20090082383A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched buprenorphine |
| CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
| US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
| ES2762113T3 (es) | 2010-01-11 | 2020-05-22 | Nalpropion Pharmaceuticals Inc | Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor |
| PL2826467T3 (pl) | 2010-12-22 | 2018-01-31 | Purdue Pharma Lp | Zamknięte, zabezpieczone przed manipulowaniem formy dozowania o kontrolowanym uwalnianiu |
| PH12013501345A1 (en) | 2010-12-23 | 2022-10-24 | Purdue Pharma Lp | Tamper resistant solid oral dosage forms |
| ME02153B (me) | 2011-09-19 | 2015-10-20 | Orexo Ab | Nove farmaceutske kompozicije, otporne na zloupotrebu, za tretman zavisnosti od opioida |
| PL4104824T3 (pl) | 2012-06-06 | 2025-11-12 | Nalpropion Pharmaceuticals Llc | Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym |
| CA2899455C (en) | 2013-01-30 | 2021-06-08 | Pharmorx Therapeutics, Inc. | Treatments for depression and other diseases with a low dose agent |
| US10751287B2 (en) | 2013-03-15 | 2020-08-25 | Purdue Pharma L.P. | Tamper resistant pharmaceutical formulations |
| DK3043777T3 (da) * | 2013-09-10 | 2020-07-20 | Fresh Cut Dev Llc | Sublingual buprenorphinspray |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| CA2946698A1 (en) * | 2014-04-22 | 2015-10-29 | Otsuka Pharmaceutical Co., Ltd. | Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders |
| US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
| CA3166250A1 (en) | 2020-02-05 | 2021-08-12 | Gregory G. Plucinski | Drug products for intranasal administration and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8332556D0 (en) * | 1983-12-06 | 1984-01-11 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| GB8430109D0 (en) | 1984-11-29 | 1985-01-09 | Gkn Technology Ltd | Securing components |
| GB8430346D0 (en) * | 1984-11-30 | 1985-01-09 | Reckitt & Colmann Prod Ltd | Analgesic compositions |
| GB8728294D0 (en) * | 1987-12-03 | 1988-01-06 | Reckitt & Colmann Prod Ltd | Treatment compositions |
| GB2213058B (en) * | 1987-12-03 | 1991-07-17 | Reckitt & Colmann Prod Ltd | Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts |
| US5472943A (en) * | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
| US5512578A (en) * | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
| US5580876A (en) * | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
| US20010006967A1 (en) * | 1992-09-21 | 2001-07-05 | Stanley M. Crain | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
| RU2077326C1 (ru) * | 1992-12-29 | 1997-04-20 | Ярыгин Владимир Никитич | Препарат для анальгезии |
| AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
| EP1280529A2 (en) * | 2000-05-05 | 2003-02-05 | Pain Therapeutics, Inc. | Opioid antagonist containing composition for enhancing the potency or reducing adverse side effects of opioid agonists |
-
2000
- 2000-11-16 AR ARP000106062A patent/AR031682A1/es unknown
- 2000-11-17 MX MXPA02004978A patent/MXPA02004978A/es active IP Right Grant
- 2000-11-17 NZ NZ519023A patent/NZ519023A/en not_active IP Right Cessation
- 2000-11-17 CA CA002392013A patent/CA2392013C/en not_active Expired - Fee Related
- 2000-11-17 WO PCT/GB2000/004372 patent/WO2001035942A2/en not_active Ceased
- 2000-11-17 CZ CZ20022121A patent/CZ303160B6/cs not_active IP Right Cessation
- 2000-11-17 EP EP00977658A patent/EP1242087B1/en not_active Expired - Lifetime
- 2000-11-17 RO ROA200200620A patent/RO121174B1/ro unknown
- 2000-11-17 KR KR1020027006375A patent/KR100726699B1/ko not_active Expired - Fee Related
- 2000-11-17 CO CO00087459A patent/CO5261517A1/es active IP Right Grant
- 2000-11-17 SI SI200020061A patent/SI21025B/sl not_active IP Right Cessation
- 2000-11-17 RU RU2002116361/15A patent/RU2255737C2/ru not_active IP Right Cessation
- 2000-11-17 PT PT00977658T patent/PT1242087E/pt unknown
- 2000-11-17 BR BR0015580-2A patent/BR0015580A/pt not_active Application Discontinuation
- 2000-11-17 ES ES00977658T patent/ES2214334T3/es not_active Expired - Lifetime
- 2000-11-17 JP JP2001537935A patent/JP4745576B2/ja not_active Expired - Fee Related
- 2000-11-17 DK DK00977658T patent/DK1242087T3/da active
- 2000-11-17 IL IL14958000A patent/IL149580A0/xx active IP Right Grant
- 2000-11-17 PL PL355330A patent/PL199727B1/pl unknown
- 2000-11-17 DE DE60009346T patent/DE60009346T2/de not_active Expired - Lifetime
- 2000-11-17 HU HU0203588A patent/HU229565B1/hu not_active IP Right Cessation
- 2000-11-17 GB GB0028088A patent/GB2356348B/en not_active Expired - Fee Related
- 2000-11-17 CN CNB008159181A patent/CN100431543C/zh not_active Expired - Fee Related
- 2000-11-17 AU AU15297/01A patent/AU777259B2/en not_active Ceased
- 2000-11-17 TR TR2004/00653T patent/TR200400653T4/xx unknown
- 2000-11-17 AT AT00977658T patent/ATE262335T1/de active
- 2000-11-17 SK SK876-2002A patent/SK286888B6/sk not_active IP Right Cessation
-
2001
- 2001-01-29 TW TW090101624A patent/TW550070B/zh not_active IP Right Cessation
-
2002
- 2002-05-09 IL IL149580A patent/IL149580A/en not_active IP Right Cessation
- 2002-05-14 US US10/145,284 patent/US6995169B2/en not_active Expired - Fee Related
- 2002-05-15 NO NO20022330A patent/NO321965B1/no not_active IP Right Cessation
-
2005
- 2005-10-20 US US11/254,525 patent/US20060069113A1/en not_active Abandoned
- 2005-10-20 US US11/254,602 patent/US7402591B2/en not_active Expired - Fee Related
- 2005-10-20 US US11/254,988 patent/US20060058333A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5261517A1 (es) | Composiciones farmaceuticas analgesicas que contienen buprenorfina/naloxona, buprenorfina/naltrexona o buprenorfina/nalmefen en bajas dosis | |
| AR065579A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| AR065580A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| WO2005039499A3 (en) | Rapidly disintegrating film | |
| ES2091441T3 (es) | Composicion farmaceutica. | |
| PE20001396A1 (es) | Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista | |
| GT200100211AA (es) | Compuestros de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos. (patentefraccionaria no. 1 de la solicitud de patente de invencion no. pi-2001-0211. | |
| ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
| WO2001082914A3 (en) | Topical anesthetic/opioid formulations and uses thereof | |
| PE20190391A1 (es) | Formas de dosificacion del tapentadol novedosas y potentes | |
| EP1444984B1 (en) | Topical pharmaceutical compositions containing natural active constituents suitable for the prevention and treatment of mucosal inflammation processes | |
| AR065581A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| NO20030897D0 (no) | Fremgangsmåte for fremstilling av farmasöytiske sammensetninger for anvendelse med blöte gelatin formuleringer | |
| AP1849A (en) | Dosage regimen and pharmaceutical composition for emergency contraception | |
| AR012417A1 (es) | COMPOSICIoN FARMACÉUTICA DE ADMINISTRACIoN ORAL Y PROCEDIMIENTO PARA SU PRODUCCION. | |
| AR065582A1 (es) | Mejoras en composiciones medicinales o relativas a las mismas | |
| ES2721899T3 (es) | Composiciones farmacéuticas que comprenden fentanilo para su administración intranasal | |
| ES2171440T3 (es) | Composicion solida mucoadhesiva, terapeutica o higienica, para administracion por aplicacion sobre la mucosa bucal o nasal. | |
| AR015744A1 (es) | Uso de dexmedetomidina para sedacion en terapia intensiva | |
| AR035946A1 (es) | Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos | |
| BR0114100A (pt) | Formulações de liberação controlada para administração oral | |
| CO5540295A2 (es) | Comprimido para tragar que comprende paracetamol | |
| AR046036A1 (es) | Composiciones de risedronato y metodos para su uso | |
| AR030957A1 (es) | Composiciones de analgesico y glucosamina | |
| ES2175663T3 (es) | Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis. |